Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 2.4 million
▲ 88% vs 2024
Profit
Growing€ 284,677
▲ 125% vs 2024
Debts
High€ 4.3 million
▼ 11% vs 2024
ONCORADIOMICS from Liège, company number BE0662719440, closed financial year 2025 with a result of € 284,677 after tax. For that financial year ONCORADIOMICS recorded a gross margin of € 2.4 million and equity of € -3,807. Compared with financial year 2024, the result moved from € -1.2 million to € 284,677. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
What happened at ONCORADIOMICS?
What happened at ONCORADIOMICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- DxOrange B.V. BO stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 284,677. Source: NBB ↗
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- Bernard Surlemont stepped down as director. NBB
- Jörg Stein stepped down as director. NBB
- DxOrange B.V. BO became a director. NBB
- NOSHAQ PARTNERS SCRL became a director. NBB
- Bernard Surlemont became a director. NBB
In short
From € 1.5 million loss in 2021 to € 284,677 profit in 2025.
Paid € 0 in corporate taxes since 2021.
Best year ever: 2025, with € 284,677 profit.
On average € 117,300 of value added per employee in 2025.
A new publication or filing at ONCORADIOMICS? We notify you, reason included.
Follow ONCORADIOMICSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Johanna Marleen Limbourg
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2023 · until 2026
Chairman of the board · represented by Jan Groen
since 2025 · until 2028
since 2023 · until 2026
Jörg Stein
Director
since 2023 · until 2026
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
Boulevard de Patience et Beaujonc 3 box 3
4000 Liège
Active since 19 September 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments
€ 5.1 million revenue · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
Hirundo Biosciences same network
€ 0 revenue · 2025
+18 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-HOSTINGER, CY
DNS
Cloudflare DNS
Domain
Domain
radiomics.bio
Registered
2020-12-14
Registrar
OVH SAS
Expires
2026-12-14
Website info
Features
Security
Details
- Company number
- 0662.719.440
- VAT number
- BE 0662.719.440
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- ONCORADIOMICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 September 2016
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- radiomics.bio
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied